The Journal of Clinical Endocrinology & Metabolism (JCEM)Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline

✅ Guideline Update

The Endocrine Society’s first comprehensive CPP guideline addresses 10 controversial diagnostic and treatment questions using GRADE methodology. Nearly all 10 recommendations are conditional with very low to low certainty evidence, reflecting reliance on observational data and a near-total absence of randomized trials.

Clinical Considerations

• Girls with thelarche between ages 7.0-8.0 years warrant watchful waiting (exams every 4-6 months) rather than immediate labs or imaging, since most have a normal adult height without treatment
• Girls younger than 7 with Tanner B2 breast development should undergo a 4- to 6-month observation period before diagnostic workup begins, to distinguish slowly progressive from rapidly progressive puberty
• Ultrasensitive basal LH is now favored as the initial diagnostic test over routine GnRH/GnRHa stimulation testing in both sexes
• Brain MRI is not routinely recommended for girls 6.0-8.0 years or boys 8.0-9.0 years without CNS symptoms, given pathologic finding rates of roughly 1% and 0%, respectively
• Routine genetic testing (MKRN3, DLK1, MECP2) is not recommended broadly but should be considered for familial CPP via shared decision-making

Practice Applications:

• Recognize that many girls 7-8 years with early thelarche do not require immediate evaluation
• Consider familial history or neurodevelopmental features before pursuing targeted genetic testing
• Monitor clinically (growth velocity, Tanner staging, bone age) rather than via routine biochemical testing during GnRHa treatment
• Avoid routinely adding growth hormone to GnRHa therapy or continuing GnRHa beyond age 10-11 (girls) or 11-12 (boys) without individualized justification